Publications

Selective liver toxicity and therapeutic progress in acute lymphoblastic leukaemia.
Bassan R.
Lancet Haematol. 2017 Aug;4(8):e346-e347. doi: 10.1016/S2352-3026(17)30121-7. Epub 2017 Jul 4

Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia.
Bassan R, Intermesoli T, Scattolin A, Viero P, Maino E, Sancetta R, Carobolante F, Gianni F, Stefanoni P, Tosi M, Spinelli O, Rambaldi A.
Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S2-S9. doi: 10.1016/j.clml.2017.02.019. Review

New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?
Patriarca F, Giaccone L, Onida F, Castagna L, Sarina B, Montefusco V, Mussetti A, Mordini N, Maino E, Greco R, Peccatori J, Festuccia M, Zaja F, Volpetti S, Risitano A, Bassan R, Corradini P, Ciceri F, Fanin R, Baccarani M, Rambaldi A, Bonifazi F, Bruno B.
Expert Opin Biol Ther. 2017 Jul;17(7):821-836. doi: 10.1080/14712598.2017.1324567. Epub 2017 May 22. Review

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS.
N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE.
Cancer. 2017 Aug 1;123(15):2875-2880. doi: 10.1002/cncr.30558. Epub 2017 Apr 7

The cell cycle checkpoint inhibitors in the treatment of leukemias.
Ghelli Luserna di Rora' A, Iacobucci I, Martinelli G.
J Hematol Oncol. 2017 Mar 29;10(1):77. doi: 10.1186/s13045-017-0443-x. Review

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Topp MS, Fielding AK, Rambaldi A, Ritchie EK, Papayannidis C, Sterling LR, Benjamin J, Stein A.
J Clin Oncol. 2017 Jun 1;35(16):1795-1802. doi: 10.1200/JCO.2016.69.3531. Epub 2017 Mar 29

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C, Papayannidis C, Venturi C, Abbenante MC, Paolini S, Parisi S, Sartor C, Cavo M, Martinelli G, Soverini S.
BMC Cancer. 2017 Aug 5;17(1):523. doi: 10.1186/s12885-017-3511-2

Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia.
De Dominici M, Porazzi P, Soliera AR, Mariani SA, Addya S, Fortina P, Peterson LF, Spinelli O, Rambaldi A, Martinelli G, Ferrari A, Iacobucci I, Calabretta B.
Cancer Res. 2018 Feb 15;78(4):1097-1109. doi: 10.1158/0008-5472.CAN-17-2644. Epub 2017 Dec 12

Blinatumomab in Ph+ B-ALL: present and perspectives.
Papayannidis C, Martinelli G.
Oncotarget. 2017 Oct 25;8(55):93309-93310. doi: 10.18632/oncotarget.22071. eCollection 2017 Nov 7. No abstract available

How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?
Gökbuget N.
Best Pract Res Clin Haematol. 2017 Sep;30(3):261-274. doi: 10.1016/j.beha.2017.07.010. Epub 2017 Aug 3. Review

Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.
Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H, Ottmann O, Pfeifer H, Trautmann H, Gökbuget N, Caliebe A, Kabelitz D, Kneba M, Horst HA, Hoelzer D, Topp MS, Cascorbi I, Siebert R, Brüggemann M.
Blood. 2017 Nov 2;130(18):2027-2031. doi: 10.1182/blood-2017-05-782888. Epub 2017 Aug 21

Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
Wilke AC, Gökbuget N.
Expert Opin Drug Saf. 2017 Oct;16(10):1191-1202. doi: 10.1080/14740338.2017.1338270. Epub 2017 Aug 20. Review

Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.
Kobitzsch B, Gökbuget N, Schwartz S, Reinhardt R, Brüggemann M, Viardot A, Wäsch R, Starck M, Thiel E, Hoelzer D, Burmeister T.
Haematologica. 2017 Oct;102(10):1739-1747. doi: 10.3324/haematol.2016.161273. Epub 2017 Jul 27

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.
Cornely OA, Leguay T, Maertens J, Vehreschild MJGT, Anagnostopoulos A, Castagnola C, Verga L, Rieger C, Kondakci M, Härter G, Duarte RF, Allione B, Cordonnier C, Heussel CP, Morrissey CO, Agrawal SG, Donnelly JP, Bresnik M, Hawkins MJ, Garner W, Gökbuget N; AmBiGuard Study Group.
J Antimicrob Chemother. 2017 Aug 1;72(8):2359-2367. doi: 10.1093/jac/dkx133

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL.
Nägele V, Kratzer A, Zugmaier G, Holland C, Hijazi Y, Topp MS, Gökbuget N, Baeuerle PA, Kufer P, Wolf A, Klinger M.
Exp Hematol Oncol. 2017 May 18;6:14. doi: 10.1186/s40164-017-0074-5. eCollection 2017

Philadelphia-Like Acute Lymphoblastic Leukemia in Adults.
Herold T, Gökbuget N.
Curr Oncol Rep. 2017 May;19(5):31. doi: 10.1007/s11912-017-0589-2. Review

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Topp MS, Fielding AK, Rambaldi A, Ritchie EK, Papayannidis C, Sterling LR, Benjamin J, Stein A.
J Clin Oncol. 2017 Jun 1;35(16):1795-1802. doi: 10.1200/JCO.2016.69.3531. Epub 2017 Mar 29

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS.
N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783

[Acute Lymphoblastic Leukaemia in Adults].
Gökbuget N.
Dtsch Med Wochenschr. 2017 Feb;142(3):170-175. doi: 10.1055/s-0042-121436. Epub 2017 Feb 10. Review. German

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Gökbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A, Horst HA, Neumann S, Brüggemann M, Ottmann OG, Burmeister T, Wessiepe D, Topp MS, Bargou R.
Haematologica. 2017 Apr;102(4):e132-e135. doi: 10.3324/haematol.2016.153957. Epub 2017 Jan 12. 

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.
Chevallier P, Chantepie S, Huguet F, Raffoux E, Thomas X, Leguay T, Marchand T, Isnard F, Charbonnier A, Maury S, Gallego-Hernanz MP, Robillard N, Guillaume T, Peterlin P, Garnier A, Rialland F, Le Houerou C, Goldenberg DM, Wegener WA, Béné MC, Dombret H.
Haematologica. 2017 May;102(5):e184-e186. doi: 10.3324/haematol.2016.159905. Epub 2017 Feb 2

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.
Lafage-Pochitaloff M, Baranger L, Hunault M, Cuccuini W, Lefebvre C, Bidet A, Tigaud I, Eclache V, Delabesse E, Bilhou-Nabéra C, Terré C, Chapiro E, Gachard N, Mozziconacci MJ, Ameye G, Porter S, Grardel N, Béné MC, Chalandon Y, Graux C, Huguet F, Lhéritier V, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).
Blood. 2017 Oct 19;130(16):1832-1844. doi: 10.1182/blood-2017-05-783852. Epub 2017 Aug 8

Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study.
Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, Cieslak A, Trinquand A, Pastoret C, Belhocine M, Spicuglia S, Lheritier V, Leprêtre S, Thomas X, Huguet F, Ifrah N, Dombret H, Macintyre E, Boissel N, Asnafi V.
J Clin Oncol. 2017 Aug 10;35(23):2683-2691. doi: 10.1200/JCO.2016.71.8585. Epub 2017 Jun 12

Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia.
Tesio M, Trinquand A, Ballerini P, Hypolite G, Lhermitte L, Petit A, Ifrah N, Baruchel A, Dombret H, Macintyre E, Asnafi V. Leukemia. 2017 Dec;31(12):2594-2600. doi: 10.1038/leu.2017.157.
Epub 2017 May 25

TCRα rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome.
Villarese P, Lours C, Trinquand A, Le Noir S, Belhocine M, Lhermitte L, Cieslak A, Tesio M, Petit A, LeLorch M, Spicuglia S, Ifrah N, Dombret H, Langerak AW, Boissel N, Macintyre E, Asnafi V. Leukemia. 2018 Jan;32(1):61-71. doi: 10.1038/leu.2017.176. Epub 2017 Jun 8

Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT.
Pavlů J, Labopin M, Zoellner AK, Sakellari I, Stelljes M, Finke J, Fanin R, Stuhler G, Afanasyev BV, Bloor AJ, Anagnostopoulos A, Mohty M, Giebel S, Nagler A.
Cancer. 2017 Jun 1;123(11):1965-1970. doi: 10.1002/cncr.30604. Epub 2017 Feb 17

Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.
Roth-Guepin G, Canaani J, Ruggeri A, Labopin M, Finke J, Cornelissen JJ, Delage J, Stuhler G, Rovira M, Potter M, Stadler M, Veelken H, Cahn JY, Collin M, Beguin Y, Giebel S, Nagler A, Mohty M.
Oncotarget. 2017 Dec 4;8(68):112972-112979. doi: 10.18632/oncotarget.22934. eCollection 2017 Dec 22

Reduction of DMSO concentration in cryopreservation mixture from 10% to 7.5% and 5% has no impact on engraftment after autologous peripheral blood stem cell transplantation: results of a prospective, randomized study.
Mitrus I, Smagur A, Fidyk W, Czech M, Prokop M, Chwieduk A, Glowala-Kosinska M, Czerw T, Sobczyk-Kruszelnicka M, Mendrek W, Michalak K, Sadus-Wojciechowska M, Najda J, Holowiecki J, Giebel S. Bone Marrow Transplant. 2018 Mar;53(3):274-280. doi: 10.1038/s41409-017-0056-6. Epub 2017 Dec 21 

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?
Ringdén O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Fløisand Y, Ghavamzadeh A, Finke J, Ehninger G, Volin L, Socié G, Kröger N, Stuhler G, Ganser A, Schmid C, Giebel S, Mohty M, Nagler A.
J Intern Med. 2018 Feb;283(2):166-177. doi: 10.1111/joim.12695. Epub 2017 Nov 3

Evaluation of proinflammatory and immunosuppressive cytokines in blood and bone marrow of healthy hematopoietic stem cell donors.
Fidyk W, Mitrus I, Ciomber A, Smagur A, Chwieduk A, Głowala-Kosińska M, Giebel S.
Cytokine. 2018 Feb;102:181-186. doi: 10.1016/j.cyto.2017.09.001. Epub 2017 Sep 18

Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Eder S, Canaani J, Beohou E, Labopin M, Sanz J, Arcese W, Or R, Finke J, Cortelezzi A, Beelen D, Passweg J, Socié G, Gurman G, Aljurf M, Stelljes M, Giebel S, Mohty M, Nagler A.
Am J Hematol. 2017 Oct;92(10):997-1003. doi: 10.1002/ajh.24823. Epub 2017 Jul 19

Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
Santoro N, Ruggeri A, Labopin M, Bacigalupo A, Ciceri F, Gülbaş Z, Huang H, Afanasyev B, Arcese W, Wu D, Koc Y, Tischer J, Santarone S, Giebel S, Mohty M, Nagler A.
J Hematol Oncol. 2017 May 30;10(1):113. doi: 10.1186/s13045-017-0480-5

Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, Ciceri F, Giebel S, Gorin NC, Savani BN, Schmid C, Nagler A.
Haematologica. 2017 Feb;102(2):224-234. doi: 10.3324/haematol.2016.148510. Epub 2016 Dec 7. Review

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Topp MS, Fielding AK, Rambaldi A, Ritchie EK, Papayannidis C, Sterling LR, Benjamin J, Stein A.
J Clin Oncol. 2017 Jun 1;35(16):1795-1802. doi: 10.1200/JCO.2016.69.3531. Epub 2017 Mar 29

Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.
Rahman S, Magnussen M, León TE, Farah N, Li Z, Abraham BJ, Alapi KZ, Mitchell RJ, Naughton T, Fielding AK, Pizzey A, Bustraan S, Allen C, Popa T, Pike-Overzet K, Garcia-Perez L, Gale RE, Linch DC, Staal FJT, Young RA, Look AT, Mansour MR.
Blood. 2017 Jun 15;129(24):3221-3226. doi: 10.1182/blood-2016-09-742148. Epub 2017 Mar 7

APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
Li Z, Abraham BJ, Berezovskaya A, Farah N, Liu Y, Leon T, Fielding A, Tan SH, Sanda T, Weintraub AS, Li B, Shen S, Zhang J, Mansour MR, Young RA, Look AT.
Leukemia. 2017 Oct;31(10):2057-2064. doi: 10.1038/leu.2017.75. Epub 2017 Mar 6

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS.
N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783

Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.
Russell LJ, Jones L, Enshaei A, Tonin S, Ryan SL, Eswaran J, Nakjang S, Papaemmanuil E, Tubio JM, Fielding AK, Vora A, Campbell PJ, Moorman AV, Harrison CJ.
Genes Chromosomes Cancer. 2017 May;56(5):363-372. doi: 10.1002/gcc.22439. Epub 2017 Jan 18

The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.
Litzow MR, Fielding AK, Luger SM, Paietta E, Ofran Y, Rowe JM, Goldstone AH, Tallman MS, Lazarus HM. Bone Marrow Transplant. 2017 Dec;52(12):1592-1598. doi: 10.1038/bmt.2017.110.
Epub 2017 Jun 5. Review

Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.
Bejanyan N, Zhang MJ, Wang HL, Lazaryan A, de Lima M, Marks DI, Sandmaier BM, Bachanova V, Rowe J, Tallman M, Kebriaei P, Kharfan-Dabaja M, Peter Gale R, Lazarus HM, Ustun C, Copelan E, Ky Hamilton B, Schiller G, Hogan W, Hashmi S, Seftel M, Kanakry CG, Olsson RF, Martino R, Saber W, Khoury HJ, Weisdorf DJ.
Biol Blood Marrow Transplant. 2018 May;24(5):945-955. doi: 10.1016/j.bbmt.2017.12.784. Epub 2017 Dec 21

Long-term survival following post-allograft relapse of T-cell acute lymphoblastic leukaemia: a novel approach using nelarabine and donor lymphocyte infusions.
Burley K, Wolf J, Raffoux E, Marks DI.
Bone Marrow Transplant. 2018 Mar;53(3):344-346. doi: 10.1038/s41409-017-0038-8. Epub 2017 Dec 21

Alemtuzumab-based therapy for Secondary Malignant Histiocytosis arising from Pre-B-ALL.
Abid MB, Wadera K, Bird JM, Pawade J, Marks DI.
Leuk Res Rep. 2017 Dec 5;9:5-8. doi: 10.1016/j.lrr.2017.11.003. eCollection 2018

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.
Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI; Acute Leukemia Committee of the CIBMTR.
Biol Blood Marrow Transplant. 2018 Apr;24(4):726-733. doi: 10.1016/j.bbmt.2017.11.025. Epub 2017 Dec 25

Post-allograft relapse of acute lymphoblastic leukemia: rational use of the new targeted therapies.
Furness CL, Marks DI. Curr Med Res Opin. 2018 Mar;34(3):517-519. doi: 10.1080/03007995.2017.1412946. Epub 2018 Jan 19

International variations in the use of haematopoietic cell transplantation for haematological malignancies: the effects of national transplant indications tables and differing access to therapies.
Protheroe RE, Bird JM, Marks DI.
Br J Haematol. 2017 Oct;179(1):5-7. doi: 10.1111/bjh.14853. Epub 2017 Aug 2. No abstract available

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI.
Lancet Haematol. 2017 Aug;4(8):e387-e398. doi: 10.1016/S2352-3026(17)30103-5. Epub 2017 Jul 4

Evaluation of coagulopathy before and during induction chemotherapy for acute lymphoblastic leukaemia, including assessment of global clotting tests.
Burley K, Salem J, Phillips T, Reilly-Stitt C, Marks DI, Tunstall O, Moppett J, Mumford A, Bradbury CA.
Blood Cancer J. 2017 Jun 16;7(6):e574. doi: 10.1038/bcj.2017.54. No abstract available

Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.
Vrooman LM, Millard HR, Brazauskas R, Majhail NS, Battiwalla M, Flowers ME, Savani BN, Akpek G, Aljurf M, Bajwa R, Baker KS, Beitinjaneh A, Bitan M, Buchbinder D, Chow E, Dandoy C, Dietz AC, Diller L, Gale RP, Hashmi SK, Hayashi RJ, Hematti P, Kamble RT, Kasow KA, Kletzel M, Lazarus HM, Malone AK, Marks DI, O'Brien TA, Olsson RF, Ringden O, Seo S, Steinberg A, Yu LC, Warwick A, Shaw B, Duncan C.
Biol Blood Marrow Transplant. 2017 Aug;23(8):1327-1334. doi: 10.1016/j.bbmt.2017.04.017. Epub 2017 Apr 28

Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
Marks DI, Liu Q, Slavin M. Expert Rev Anti Infect Ther. 2017 May;15(5):493-502. doi: 10.1080/14787210.2017.1305886.
Epub 2017 Mar 24. Review

Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?
Dhawan R, Marks DI.
Curr Hematol Malig Rep. 2017 Apr;12(2):143-152. doi: 10.1007/s11899-017-0371-4. Review. 

Management of adults with T-cell lymphoblastic leukemia.
Marks DI, Rowntree C.
Blood. 2017 Mar 2;129(9):1134-1142. doi: 10.1182/blood-2016-07-692608. Epub 2017 Jan 23. Review. Erratum in: Blood. 2017 Apr 13;129(15):2204.

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.
Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS.
Bone Marrow Transplant. 2017 Mar;52(3):400-408. doi: 10.1038/bmt.2016.265. Epub 2016 Dec 12

A Stem Cell Donor for Every Adult Requiring an Allograft for Acute Lymphoblastic Leukemia?
Marks DI, Abid MB.
Biol Blood Marrow Transplant. 2017 Feb;23(2):182-183. doi: 10.1016/j.bbmt.2016.11.019.
Epub 2016 Nov 24

CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.
Legut M, Dolton G, Mian AA, Ottmann OG, Sewell AK.
Blood. 2018 Jan 18;131(3):311-322. doi: 10.1182/blood-2017-05-787598. Epub 2017 Nov 9.

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Gökbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A, Horst HA, Neumann S, Brüggemann M, Ottmann OG, Burmeister T, Wessiepe D, Topp MS, Bargou R.
Haematologica. 2017 Apr;102(4):e132-e135. doi: 10.3324/haematol.2016.153957. Epub 2017 Jan 12

Plastic CD34 and CD38 expression in adult B-cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations.
Lang F, Wojcik B, Bothur S, Knecht C, Falkenburg JH, Schroeder T, Serve H, Ottmann OG, Rieger MA.
Leukemia. 2017 Mar;31(3):731-734. doi: 10.1038/leu.2016.315. Epub 2016 Nov 2

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T, Wels WS.
Cytotherapy. 2017 Feb;19(2):235-249. doi: 10.1016/j.jcyt.2016.10.009. Epub 2016 Nov 22

Rescue treatment of patients with relapsed acute leukemia after first allogeneic hematopoietic stem cell transplantation.
Torrent A, Ferrá C, Ribera JM.
Med Clin (Barc). 2017 Dec 30. pii: S0025-7753(17)30928-4. doi: 10.1016/j.medcli.2017.11.044. [Epub ahead of print] English, Spanish

Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation.
Rovó A, Kulasekararaj A, Medinger M, Chevallier P, Ribera JM, Peffault de Latour R, Knol C, Iacobelli S, Kanfer E, Bruno B, Maury S, Quarello P, Koh MBC, Schouten H, Blau IW, Tichelli A, Hill A, Risitano A, Passweg J, Marsh J, Dreger P, Dufour C.
Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15074. [Epub ahead of print] 

Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, Bermúdez A, Moreno MJ, González-Campos J, Vives S, Gil C, Abella E, Guàrdia R, Martínez-Carballeira D, Martínez-Sánchez P, Amigo ML, Mercadal S, Serrano A, López-Martínez A, Vall-Llovera F, Sánchez-Sánchez MJ, Peñarrubia MJ, Calbacho M, Méndez JA, Bergua J, Cladera A, Tormo M, García-Belmonte D, Feliu E, Ciudad J, Orfao A; PETHEMA Group, Spanish Society of Hematology.
Leuk Lymphoma. 2017 Nov 22:1-10. doi: 10.1080/10428194.2017.1397661. [Epub ahead of print] 

Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM.
Expert Rev Hematol. 2017 Dec;10(12):1057-1067. doi: 10.1080/17474086.2017.1396890. Epub 2017 Nov 1. 

Second neoplasms in adult patients submitted to haematopoietic stem cell transplantation.
Torrent A, Ferrá C, Morgades M, Jiménez MJ, Sancho JM, Vives S, Batlle M, Moreno M, Xicoy B, Oriol A, Ibarra G, Ribera JM. Med Clin (Barc). 2018 Jun 8;150(11):421-427. doi: 10.1016/j.medcli.2017.07.004.
Epub 2017 Sep 2. English, Spanish

Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms.
Ribera J, Zamora L, Morgades M, Mallo M, Solanes N, Batlle M, Vives S, Granada I, Juncà J, Malinverni R, Genescà E, Guàrdia R, Mercadal S, Escoda L, Martinez-Lopez J, Tormo M, Esteve J, Pratcorona M, Martinez-Losada C, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group and the Spanish Society of Hematology.
Genes Chromosomes Cancer. 2017 Nov;56(11):810-820. doi: 10.1002/gcc.22486. Epub 2017 Aug 26

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M, Robledo C, Benito R, Bodega-Mayor I, Rapado I, Hernández-Sánchez M, Abáigar M, Maria Hernández-Sánchez J, Quijada-Álamo M, María Sánchez-Pina J, Sala-Valdés M, Araujo-Silva F, Kohlmann A, Luis Fuster J, Arefi M, de Las Heras N, Riesco S, Rodríguez JN, Hermosín L, Ribera J, Camos Guijosa M, Ramírez M, de Heredia Rubio CD, Barragán E, Martínez J, Ribera JM, Fernández-Ruiz E, Hernández-Rivas JM.
Br J Cancer. 2017 Jul 11;117(2):256-265. doi: 10.1038/bjc.2017.152. Epub 2017 May 30

Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.
Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, González-Campos J, Moreno MJ, Barba P, Cervera M, Barrios M, Novo A, Bernal T, Hernández-Rivas JM, Abella E, Amigo ML, Tormo M, Martino R, Lavilla E, Bergua J, Serrano A, García-Belmonte D, Guàrdia R, Grau J, Feliu E; PETHEMA Group, Spanish Society of Hematology.
Leuk Lymphoma. 2018 Jan;59(1):146-154. doi: 10.1080/10428194.2017.1326596.
Epub 2017 May 30

Acute lymphoblastic leukemia in adults: Steps ahead.
Ribera JM, Vives S.
Med Clin (Barc). 2017 Aug 10;149(3):119-121. doi: 10.1016/j.medcli.2017.03.027. Epub 2017 Apr 26. English, Spanish

Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
Sanchez R, Ayala R, Alonso RA, Martínez MP, Ribera J, García O, Sanchez-Pina J, Mercadal S, Montesinos P, Martino R, Barba P, González-Campos J, Barrios M, Lavilla E, Gil C, Bernal T, Escoda L, Abella E, Amigo ML, Moreno MJ, Bravo P, Guàrdia R, Hernández-Rivas JM, García-Guiñón A, Piernas S, Ribera JM, Martínez-López J.
Ann Hematol. 2017 Jul;96(7):1069-1075. doi: 10.1007/s00277-017-3002-1. Epub 2017 Apr 27

Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.
Anadón C, van Tetering G, Ferreira HJ, Moutinho C, Martínez-Cardús A, Villanueva A, Soler M, Heyn H, Moran S, Castro de Moura M, Setien F, Vidal A, Genescà E, Ribera JM, Nomdedeu JF, Guil S, Esteller M.
Leukemia. 2017 Jul;31(7):1622-1625. doi: 10.1038/leu.2017.99. Epub 2017 Mar 27

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS.
N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783